<DOC>
	<DOCNO>NCT00750880</DOCNO>
	<brief_summary>This open-label , single arm study investigate safety , tolerability efficacy tocilizumab monotherapy , combination therapy non-biologic disease modify antirheumatic drug ( DMARDs ) , patient severe active RA . Patients receive tocilizumab 8mg/kg iv 60 minute infusion every 4 week total 6 infusion . The anticipated time study treatment 3-12 month , target sample size &gt; 500 individual .</brief_summary>
	<brief_title>An Exploratory Study Tocilizumab Patients With Active Rheumatoid Arthritis ( RA ) Inadequate Response Current Non-Biologic DMARDs and/or Anti-TNF Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>male nonpregnant nursing female patient &gt; =18 year age ; body weight &lt; =150kg ; moderate severe active RA ( DAS28 &gt; =3.2 ) &gt; =6 month duration ; &gt; =1 nonbiologic DMARDs stable dose period &gt; = 8 week prior start treatment ; inadequate clinical response stable dose nonbiologic DMARD antiTNF therapy ; receive oral corticosteroid , dose must stable least 25 28 day prior start treatment . major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow enrollment ; rheumatic autoimmune disease RA ; prior history , current inflammatory joint disease RA ; functional class IV define ACR Classification Functional Status RA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>